Accordingly, ECC-BYF III, ER, and the combination of ECC-BYF III and ER may improve AMH in COPD rats through inhibiting EGFR and downstream MAPK pathways including ERK, JNK, and p38 signaling. The gene discussed is MAPK8; the disease is chronic obstructive pulmonary disease.